Paul Peter Tak
Paul Peter Tak is a business leader, academic, entrepreneur and clinician who has over 30 years’ experience in medicine as a prominent expert in Immunology, Internal Medicine, and Rheumatology. Paul Peter is currently the President, CEO, and Board Director of Candel Therapeutics, the Co-Founder and Board Director of Sitryx Therapeutics, Board Director of Levicept and Chair of Citryll.
Alongside his industry career, Paul Peter has dedicated much of his life to academia and advancing our understanding in medicine. He has served as Professor of Medicine at the University of Amsterdam and holds numerous honours for his service to medicine, with a special focus on Immunology and Rheumatology.
What about an off-the-shelf pan-solid tumor investigational medicine that induces an individualized anti-tumor immune response?
Exciting to see that finally that big pharma has woken to the race to find a cancer vaccine. What is needed is the PERSONALIZED mutations that make up the components of that vaccine…and we began that quest since 2015 at NANTOMICS!
Now the fundamental computing methods have been
During #ProstateCancerAwarenessMonth, we recognize patients fighting this disease.
Candel is advancing aglatimagene for intermediate- to high-risk localized prostate cancer, with phase 3 data showing meaningful improvements in disease-free survival.
https://candeltx.com/
